文献速递泌尿男性生殖肿瘤

基于磁共振成像的前列腺活检风险分层预测模型

A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.
PubMed 文献 · JAMA Oncol · 2018-01-01

本研究开发并验证了一个基于MRI参数的前列腺癌活检风险预测模型。

要点

  • MRI模型在外部验证中AUC达84%,优于基线模型64%(P<.001)。
  • 20%阈值下,MRI模型假阳性率46% vs 基线92%,真阳性率89% vs 99%。

核心结论

  • 将MRI参数纳入风险模型可减少不必要的活检,同时保持对临床显著前列腺癌的高诊断率。

研究设计与样本

  • 开发队列为单中心400例患者(2015年5月14日至2016年8月31日入组),验证队列为2家独立机构251例患者(活检时间分别为2013年4月1日至2016年6月30日、2015年7月1日至2016年10月31日)。
  • 所有患者均接受MRI、MRI-TRUS融合引导活检和12针系统活检。
  • MRI模型包含MRI衍生参数及临床变量,采用ROC曲线下面积和决策曲线分析。

主要发现

  • 开发队列400例中193例(48.3%)和验证队列251例中96例(38.2%)检出临床显著前列腺癌(Gleason评分≥3+4)。
  • 外部验证中,MRI模型AUC从基线模型的64%提高至84%(P<.001)。
  • 在20%风险阈值下,MRI模型假阳性率46%(95%CI 32%-66%)低于基线模型92%(95%CI 70%-100%),真阳性率89%(95%CI 85%-96%)略低于基线模型99%(95%CI 89%-100%)。

关键数值与推荐

  • 临床显著前列腺癌定义为至少1个活检核心Gleason评分≥3+4。
  • 风险阈值20%下,MRI模型假阳性率46%(95%CI 32%-66%),基线模型92%(95%CI 70%-100%)。
  • 风险阈值20%下,MRI模型真阳性率89%(95%CI 85%-96%),基线模型99%(95%CI 89%-100%)。

临床怎么用

  • 对于疑似前列腺癌患者,可采用基于MRI参数的预测模型进行风险分层,辅助决定是否进行活检。
  • 在20%风险阈值下应用该模型,可能减少不必要的活检而不明显增加临床显著前列腺癌的漏诊。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Multiparametric magnetic resonance imaging (MRI) in conjunction with MRI-transrectal ultrasound (TRUS) fusion-guided biopsies have improved the detection of prostate cancer. It is unclear whether MRI itself adds additional value to multivariable prediction models based on clinical parameters. OBJECTIVE: To determine whether an MRI-based prediction model can reduce unnecessary biopsies in patients with suspected prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Patients underwent MRI, MRI-TRUS fusion-guided biopsy, and 12-core systematic biopsy in 1 session. The development cohort used to derive the prediction model consisted of 400 patients from 1 institution enrolled between May 14, 2015, and August 31, 2016, and the validation cohort included 251 patients from 2 independent institutions who underwent biopsies between April 1, 2013, and June 30, 2016, at 1 institution and between July 1, 2015, and October 31, 2016, at the other institution. The MRI model included MRI-derived parameters in addition to clinical variables. Area under the curve of receiver operating characteristic curves and decision curve analysis were performed. MAIN OUTCOMES AND MEASURES: Risk of clinically significant prostate cancer on biopsy, defined as a Gleason score of 3 + 4 or higher in at least 1 biopsy core. RESULTS: Overall, 193 (48.3%) of the 400 patients in the development cohort (mean [SD] age at biopsy, 64.3 [7.1] years) and 96 (38.2%) of the 251 patients in the validation cohort (mean [SD] age at biopsy, 64.9 [7.2] years) had clinically significant prostate cancer, defined as a Gleason score greater than or equal to 3 + 4. By applying the model to the external validation cohort, the area under the curve increased from 64% to 84% compared with the baseline model (P < .001). At a risk threshold of 20%, the MRI model had a lower false-positive rate than the baseline model (46% [95% CI, 32%-66%] vs 92% [95% CI, 70%-100%]), with only a small reduction in the true-positive rate (89% [95% CI, 85%-96%] vs 99% [95% CI, 89%-100%]). Eighteen of 100 fewer biopsies could have been performed, with no increase in the number of patients with missed clinically significant prostate cancers. CONCLUSIONS AND RELEVANCE: The inclusion of MRI-derived parameters in a risk model could reduce the number of unnecessary biopsies while maintaining a high rate of diagnosis of clinically significant prostate cancers.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mehralivand S, Shih JH, Rais-Bahrami S, et al. A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification. JAMA Oncol. 2018. PMID: 29470570. doi:10.1001/jamaoncol.2017.5667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。